Pharmacokinetics: A Modern View

Front Matter....Pages i-xvi
Sidney Riegelman — The Wisconsin Years....Pages 1-5
Sidney Riegelman — Friend and Colleague....Pages 7-10
Sidney Riegelman — The Educator....Pages 11-16
Sidney Riegelman — The Scientist....Pages 17-22
Sidney Riegelman — His Contributions to Public Policy in Pharmacy and The Pharmaceutical Sciences....Pages 23-29
Sidney Riegelman — Contributions at the Clinical Interface....Pages 31-36
Personal Experiences in the Early Days of Biopharmacy and Pharmacokinetics....Pages 37-54
Modern Pharmaceutical Dosage Forms....Pages 55-65
Specificity of Esterases and Effect of Structure of Prodrug Esters of Acylated Acetaminophen on Hydrolytic Reactivity....Pages 67-82
Transdermal Absorption: A Unique Opportunity for Drug Delivery....Pages 83-96
Pharmacokinetics and Pharmaceutical Technology....Pages 97-111
Bioavailability and Pharmacokinetics in Drug Development....Pages 113-132
Clearance — Models, Validation and Implications....Pages 133-146
Estimation of an Effective Half-Life....Pages 147-162
Pharmacokinetic Aspects of Nonlinear Drug-Protein Binding....Pages 163-172
Unusual Pharmacokinetics....Pages 173-189
Assessment and Prediction of In Vivo Oxidative Drug Metabolizing Activity....Pages 191-216
Pharmacokinetic and Pharmacological Aspects of Polymorphic Drug Oxidation in Man....Pages 217-234
Problems in Correlating In Vitro and In Vivo Studies of Drug Metabolism....Pages 235-252
Integral Procedures in Pharmacokinetics and their Application to the Parameter Determination of Appearing Metabolites....Pages 253-279
Pharmacokinetics at the Interface Between Pharmacology and Physiology....Pages 281-293
Methods for Drug Dosage Individualization: Past, Present and Future....Pages 295-314
Treatment of Depression — Pharmacokinetic and Pharmacogenetic Considerations....Pages 315-325
Kinetics of Drug Action....Pages 327-343
Cancer Drug Delivery Systems: Macromolecular Prodrugs of Mitomycin C....Pages 345-358
Organ Variation in Tissue to Plasma Partition Coefficients of Adriamycin, Daunomycin and Actinomycin-D: Correlation to Tissue DNA Concentrations....Pages 359-378
Clinical Pharmacokinetics in the Therapeutic Management of Cancer Patients with Methotrexate and Adriamycin....Pages 379-388
The Immunopharmacokinetics of Prednisone/Prednisolone....Pages 389-402
The Interpretation of In Vivo Mean Dissolution Time Data....Pages 403-406
Application of Statistical Moment Analysis to the Evaluation of Controlled Release Formulations....Pages 407-410
Concept of Time-Averaged Total Clearance and Mean Residence Time in Michaelis-Menten Elimination Systems....Pages 411-414
A General Method of Optimizing Individual Drug Dosage....Pages 415-417
Estimation of Population Pharmacokinetic Parameters with the Computer System Nonmem: Patients Treated with Lidocaine and Mexiletine....Pages 418-421
Considerations of Linear Regression with Errors in both Variables as Applied to Clinical Pharmacokinetics....Pages 422-425
Intestinal Drug Metabolism — Presystemic and Systemic Mechanisms and Implications....Pages 426-429
Pharmacokinetics of Aspirin: Total and Presystemic Clearance by Rats and Hydrolysis in Blood of Rats and Humans....Pages 430-432
Do Plasma Concentrations of Acetaminophen and its Conjugated Metabolites Reflect Concentrations in Various Tissues?....Pages 433-437
Interspecies Variations in Pharmacokinetics: A Perspective....Pages 438-441
Nonrenal Elimination, Extensive Renal Tubular Reabsorption and Secretion of Creatinine in Humans and Animals....Pages 442-444
Phenobarbital Pharmacokinetics with Particular Emphasis on the Treatment of Overdosed Patients....Pages 445-448
Renal Elimination in Alcoholic Cirrhosis....Pages 449-451
Altered Disposition of Naproxen by Cirrhotic and by Elderly Individuals....Pages 452-455
Drug-Drug Interactions: Protean Manifestations....Pages 456-458
Kinetics and Antiarrhythmic Effect of Dihydroquinidine....Pages 459-462
Quinidine-N-Oxide: Structure and Pharmacokinetics of a New Quinidine Metabolite....Pages 463-466
Phenobarbital Induction of Quinidine Plasma Protein Binding in Dogs and its Effect on Quinidine Disposition....Pages 467-470
Covalent Binding of Quinidine....Pages 471-473
The Use of the Portacaval Transposition Technique to Study Gastrointestinal and Hepatic Metabolism of Propranolol in Dogs....Pages 474-477
Stereoselective Disposition and Glucuronidation of Propranolol in Man....Pages 478-480
Effect of Renal and Hepatic Insufficiency on the Pharmacokinetics of Betaxolol, A New Adrenergic ß-Blocker....Pages 481-483
A Selective HPLC Assay for Simultaneous Quantitation of Fourteen Methylxanthines and Methyluric Acids in Urine....Pages 484-487
A Composite View of Theophylline Elimination in Man....Pages 488-491
The Influence of Food on the Bioavailability of a Sustained Release Theophylline Formulation....Pages 492-496
Pharmacokinetics of the Vasodilators Hydralazine and Endralazine....Pages 497-499
Formation of Mono- and Dinitrate Metabolites of Nitroglycerin Following Incubation with Human Blood....Pages 500-503
A Pharmacodynamic Model for Thiazinamium in Asthmatic Patients....Pages 504-507
Protein Binding Estimates in the Presence of Volume Shifts During Equilibrium Dialysis....Pages 508-511
Opiate Pharmacokinetics: In Vivo Receptor Binding and Pharmacological Effects....Pages 512-515
Cefoperazone Pharmacokinetics in Healthy Chinese Volunteers....Pages 516-518
Back Matter....Pages 519-531